|
Report Date : |
22.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
FITZGERALD INDUSTRIES INTERNATIONAL, INC. |
|
|
|
|
Registered Office : |
30 Sudbury Road, Ste 1A North, Acton, MA 01720 |
|
|
|
|
Country : |
United States |
|
|
|
|
Year of Establishment: |
1989 |
|
|
|
|
Legal Form : |
Corporation – Profit |
|
|
|
|
Line of Business : |
manufacturer and supplier
of antibodies, proteins, and research products for researchers, diagnostic
companies, and pharmaceutical manufacturers worldwide. |
|
|
|
|
No. of Employees : |
14 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
united StaTes ECONOMIC OVERVIEW
The US has the largest and most
technologically powerful economy in the world, with a per capita GDP of
$49,800. In this market-oriented economy, private individuals and business firms
make most of the decisions, and the federal and state governments buy needed
goods and services predominantly in the private marketplace. US business firms
enjoy greater flexibility than their counterparts in Western Europe and Japan
in decisions to expand capital plant, to lay off surplus workers, and to
develop new products. At the same time, they face higher barriers to enter
their rivals' home markets than foreign firms face entering US markets. US
firms are at or near the forefront in technological advances, especially in
computers and in medical, aerospace, and military equipment; their advantage
has narrowed since the end of World War II. The onrush of technology largely
explains the gradual development of a "two-tier labor market" in
which those at the bottom lack the education and the professional/technical
skills of those at the top and, more and more, fail to get comparable pay
raises, health insurance coverage, and other benefits. Since 1975, practically
all the gains in household income have gone to the top 20% of households. Since
1996, dividends and capital gains have grown faster than wages or any other
category of after-tax income. Imported oil accounts for nearly 55% of US
consumption. Crude oil prices doubled between 2001 and 2006, the year home
prices peaked; higher gasoline prices ate into consumers' budgets and many
individuals fell behind in their mortgage payments. Oil prices climbed another
50% between 2006 and 2008, and bank foreclosures more than doubled in the same
period. Besides dampening the housing market, soaring oil prices caused a drop
in the value of the dollar and a deterioration in the US merchandise trade
deficit, which peaked at $840 billion in 2008. The sub-prime mortgage crisis,
falling home prices, investment bank failures, tight credit, and the global
economic downturn pushed the United States into a recession by mid-2008. GDP
contracted until the third quarter of 2009, making this the deepest and longest
downturn since the Great Depression. To help stabilize financial markets, in
October 2008 the US Congress established a $700 billion Troubled Asset Relief
Program (TARP). The government used some of these funds to purchase equity in
US banks and industrial corporations, much of which had been returned to the
government by early 2011. In January 2009 the US Congress passed and President
Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus
to be used over 10 years - two-thirds on additional spending and one-third on
tax cuts - to create jobs and to help the economy recover. In 2010 and 2011,
the federal budget deficit reached nearly 9% of GDP. In 2012 the federal
government reduced the growth of spending and the deficit shrank to 7.6% of
GDP. Wars in Iraq and Afghanistan required major shifts in national resources
from civilian to military purposes and contributed to the growth of the budget
deficit and public debt. Through 2011, the direct costs of the wars totaled
nearly $900 billion, according to US government figures. US revenues from taxes
and other sources are lower, as a percentage of GDP, than those of most other
countries. In March 2010, President OBAMA signed into law the Patient
Protection and Affordable Care Act, a health insurance reform that will extend
coverage to an additional 32 million American citizens by 2016, through private
health insurance for the general population and Medicaid for the impoverished.
Total spending on health care - public plus private - rose from 9.0% of GDP in
1980 to 17.9% in 2010. In July 2010, the president signed the DODD-FRANK Wall
Street Reform and Consumer Protection Act, a law designed to promote financial
stability by protecting consumers from financial abuses, ending taxpayer
bailouts of financial firms, dealing with troubled banks that are "too big
to fail," and improving accountability and transparency in the financial
system - in particular, by requiring certain financial derivatives to be traded
in markets that are subject to government regulation and oversight. In December
2012, the Federal Reserve Board announced plans to purchase $85 billion per
month of mortgage-backed and Treasury securities in an effort to hold down
long-term interest rates, and to keep short term rates near zero until
unemployment drops to 6.5% from the December rate of 7.8%, or until inflation
rises above 2.5%. Long-term problems include stagnation of wages for
lower-income families, inadequate investment in deteriorating infrastructure,
rapidly rising medical and pension costs of an aging population, energy
shortages, and sizable current account and budget deficits - including
significant budget shortages for state governments.
|
Source : CIA |
Company name: FITZGERALD INDUSTRIES INTERNATIONAL, INC.
Address: 30 Sudbury Road, Ste 1A
North, Acton, MA 01720 - USA
Telephone: +1
978-371-6446
Fax: +1 978-371-2266
Website: www.fitzgerald-fii.com
Corporate ID#: 3783311
State: Delaware
Judicial form: Corporation – Profit
Date incorporated: 03-29-2004
Date founded: 1989
Stock: 1,000
shares common
Value: USD
0.01= par value
Name of manager: Ronan
O’CAOIMH
Business:
Fitzgerald Industries International, Inc. manufactures and supplies
antibodies, proteins, and research products for researchers, diagnostic
companies, and pharmaceutical manufacturers worldwide.
It provides antibodies, such as unconjugated and conjugated monoclonal
antibodies; unconjugated, purified, and conjugated polyclonal antibodies; and
unconjugated, purified, and conjugated secondary antibodies.
The company also offers proteins, including recombinant proteins,
conjugated proteins, hapten conjugates, complements, blocking peptides, and
native proteins; animal serum and red blood cells, and human serum and plasma;
research kits; specialty products that include poly-HRP products, diluents,
chemical reference, and colloidal gold and silver products; and other reagents,
such as surfactants, mounting media and preservatives, controls and
calibrators, IHC reagents, and substrates.
It markets and sells its products through distributors in the United
States and internationally; and online.
The company was founded in 1989 and is headquartered in Acton,
Massachusetts. As of April 20, 2004, Fitzgerald Industries International, Inc.
operates as a subsidiary of Trinity Biotech plc.
The Company exports worldwide.
EIN: 20-1081946
Staff: 14
Operations & branches:
At the headquarters, we
find a laboratory and office, on lease.
Shareholders:
Trinity Biotech plc
IDA Business Park
Bray, Ireland
Trinity Biotech plc acquires, develops, manufactures, and markets
medical diagnostic products for the clinical laboratory and point-of-care (POC)
segments of the diagnostic market. It offers clinical laboratory products,
including diagnostic tests and instrumentation, which detect infectious
diseases, such as bacterial and viral diseases, and autoimmune disorders;
products for the in-vitro diagnostic testing for haemoglobin A1c (HbA1c) used
in the monitoring and diagnosis of diabetes; Hb variants for the detection of
Hemoglobinapothies; and reagent products, such as ACE, bile acids, lactate,
oxalate, and glucose-6-phosphate dehydrogenase for detecting liver and kidney
diseases, and haemolytic anaemia. The company also provides UniGold HIV, a POC
diagnostic test, which is carried out in the presence of the patient to
diagnose the presence of HIV antibodies in the patient. In addition, it sells
raw materials to the life sciences industry and research institutes.
Its customers include hospitals, clinical and reference laboratories,
public health facilities, and other outreach facilities. The company sells its
products through its direct sales force in the United States; and a network of
independent distributors and strategic partners internationally.
Trinity Biotech plc was founded in 1992 and is headquartered in Bray,
Ireland.
Management:
Ronan O’CAOIMH is the President.
He co-founded Trinity Biotech PLC in June 1992 and has been its Chief
Executive Officer since October 2008. Mr. O'Caoimh served as the Chief
Executive Officer of Trinity Biotech PLC from March 1994 to November 2007 and
as its Chief Financial Officer until March 1994. He served as Finance Director
of Noctech Limited from 1988 to January 1991 and served as its Managing
Director.
He has been Chairman of the Board of Trinity Biotech PLC since May 1995
and also serves as its Director.
He practiced as Chartered Accountant at Arthur Andersen, Dublin.
Mr. O'Caoimh holds Bachelor of Commerce from University College, Dublin
and is Fellow of the Institute of Chartered Accountants in Ireland.
Pamela WILLIAMS is Vice President
Beverly ISAMAN is Secretary
Subsidiaries
& partnership:
None
In United States and
Canada, privately held corporations are not required to publish any financials.
On a direct call, nobody
accepted to answer our questions.
We sent a fax but no answer
received.
Sales declared for year
2012 is in the range of USD 10,000,000=
The business is profitable.
Banks: Citibank
Legal filings
& complaints:
As of today date, there is no legal filing pending with the Courts.
Secured debts summary (UCC):
None